




Baseline-adjusted average P50 gating ratio (T/C) as a function of group assignment [F=1.16, P=0.36]. The standard errors of each mean are noted in the legend. The bars left to right represent placebo, 0.3 mg test compound, and 1.0 mg test compound



Baseline-adjusted average P50 difference (C-T) as a function of group assignment [F=3.97, P=0.07]. The standard errors of each mean are noted in the legend. The bars left to right represent placebo, 0.3 mg test compound, and 1.0 mg test compound


FIG. 1



Baseline-adjusted average N100 gating ratio (T/C) as a function of group assignment [F=3.04, P=0.10]. The standard errors of each mean are noted in the legend. The bars left to right represent placebo, 0.3 mg test compound, and 1.0 mg test compound

Baseline-adjusted average N100 difference (C-T) as a function of group assignment [F=1.02, P=0.38]. The standard errors of each mean are noted in the legend. The bars left to right represent placebo, 0.3 mg test compound, and 1.0 mg test compound

FIG. 2


MMN SUMMED AMPLITUDE
(RARE-FREQUENT)
0.2
0
-0.2
-0.4
-0.6
-0.8
-1
-1.2
0.14
-0.61
-1.15
Placebo (SE=.33)
0.3 mg (SE=.25)
1.0 mg (SE=.24)



P300 AMPLITUDE
(PEAK - PRESTIMULUS
VOLTAGE)
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
1.08
0.78
-0.3
Placebo (SE=.31)
0.3 mg (SE=.24)
1.0 mg (SE=.22)

FIG. 3